In patients with HNSCC treated with pembrolizumab the TMB was also predictive of improved response, independent of other factors such as PD-L1 expression and T-cell inflamed gene expression profile (GEP) [97,98,99]. Here, CD274 is linked to head and neck squamous cell carcinoma.